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to AVNes seen either preablation or during ablation attempts when tachycar-
dia was still inducible (bad echoes) (366.9 ± 113 vs 279.6 ± 80 msec, p <
0.001). In Group 2 patients, when the AH interval of AVNes was unchanged
from baseline, further ablation attempts were required to achieve nonin-
ducibility and also resulted in abolition of dual physiology. During a mean
follow-up of 11 ± 4 months, only one of the 96 patients had a recurrence.
Conclusion: Successful modification of the slow pathway for AVNRT is
associated with persistent AVNes with longer AH intervals possibly due to
slow pathway injury or multiple slow pathways. Post ablation, AVNes with
unchanged AH interval from baseline require further ablation for successful
outcome.
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1724-31 Long RP Tachycardia: Can Mode of Termination by
Adenosine Differentiate Atrial from Atypical AV Node
Re-entry Tachycardia?
John Hill, Rafe Chamberlain Webber, Leandro Zimerman, Hossein Shenasa,
Richard Fogel, Marcus Wharton, Eric Prystowsky. Indiana Heart Institute,
Indianapolis, IN; Duke University Medical Center, Durham, NC
Discrimination between long RP tachycardias can be difficult but is essential
when ablative therapy is contemplated. After diagnosis by EP study, we ad-
ministered adenosine (Ad) 12 mg to pts during atrial (AT, n ~ 24) or atypical
AV node (ATYP, n = 7) tachycardia (tc). Tc cycle length (Cl) and component in-
tervals were measured before and after Ad. Ad caused termination (term) in
all AT without prior AV node block. In tc without substantial Cl variability, first
change (8) in Cl after Ad was located in either H-H or A-A intervals. For cycles
between 8 and term in atrium (a) or ventricle (v), presence of Cl oscillation
(Osc) and net change of A-A were assessed and intervals were examined for
Pearson r linear correlation patterns.
1. Before Ad age sex CL A-H H-A
(y) (m, f) Ims) (ms) (ms)
AT 43 ± 17 2, 22 425 ± 94 82 ± 52 332 ± 107
ATYP 38 ± 20 3, 4 387 ± 107 113 ± 70 289 ± 86
p: ns <0.005 ns ns ns
2. After Ad 8 Ose term 8 to term net 11M
(A-A, H-H) (nJ (a, vi (cyclesl (msl
AT 17 0 15 10 14 3.9± 14 28± 29
ATYP 2 2 6 2 5 3.5 ± 1.7 25 ± 24
p: ns ns ns ns ns ns ns
3. A-Avs A-H A-Avs H-A
(term a) (term v) (term a) (term vi
No. of Correlations AT 6/10 2/14 4/10 13/14
with p < 0.05 for r ATYP 1/2 1/5 2/2 3/5
P (AT vs ATYP): ns ns ns ns
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The earliest atrial activation during SF reentry was recorded at the His bun-
dle electrogram, while during FS reentry it was recorded anterior and inferior
to the coronary sinus ostium. A single radiofrequency (RF) application at the
earliest atrial site during FS reentry eliminated both the FS echoes and the ret-
rograde discontinuous curve, while maintaining a discontinuous antegrade
curve (figure) and SF reentry (non sustained in one patient and sustained in
the other patientl. In the latter patient, complete elimination of the slow path-
way and SF reentry was achieved by further RF applications approximately 1
cm above the ablation site for FS reentry.
Conclusion: Prevention of atypical AVN echoes does not necessarily abol-
ish the typical form of AVN reentry. This suggests that the atypical form is not
simply a "reverse" of the typical form of AVN reentry.
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1724-51 Retrograde Atrial Activation in Patients with
Atrioventricular Nodal Reentry: Evidence for a Single
Anterior Nodal Exit
Michael Biehl, Sanjay Deshpande, Jasbir Sra, Anwer Dhala, Zalmen Blanck, R.
Dent Underwood, Edward T. Keelan, Masood Akhtar, Mohammad Jazayeri. Sinai
SamaritanlSt Lukes Medical Center, Milwaukee, WI
Recent reports suggested different retrograde atrial break throughs dur-
ing right ventricular apical (RVA) pacing at cycle lengths (Cl) of >600 and
<500 msec or change in the atrial electrogram morphology with critically
timed ventricular premature beats (V2) during atioventricular nodal reentrant
tacycardia (AVNRT). These Observations were attributed to the presence of
anisotropic conduction properties and multiple anterior nodal exits. respec-
tively. We evaluated the sequence of retrograde atrial activation in 12 con-
secutive patients (pts) with AVNRT. Using hexa- or decapolar catheters with
2 mm interelectrode spacing, multiple electrograms were recorded from the
His bundle region, posteroseptal, and midseptal tricuspid annulus. Atrial acti-
vation was assessed during decremental (RVA) pacing at CL 700 to 400 msec
(50 msec decrements) and down to the cycle length of block thereafter (10
msec decrements). and during diastolic scanning of AVNRTwith V2 (10 msec
decrements).
The mean cycle length of tachycardia was 366 msec. The atrial retrograde
activation sequence during decremental RVA pacing was identical to that dur-
ing AVNRT for all pts. At critical coupling intervals, V2 could penetrate AVNRT
circuit as indicated by resetting the tachycardia cycle length in 9 pts. In each
patient, resetting or lack of resetting was associated with a change in mor-
phology in all intracardiac electrograms when the local V2 and A2 were sepa-
rated. The sequence of atrial activation remained unchanged and identical to
that during tachycardia in all pts.
Conclusion: These observations suggest that only one retrograde pathway
links the distal AV node to the anterior atrial septum. Change in electrogram
morphology is most likely due to isolating ventricular from atrial activation.
AVNRT could be reset from the atrium and from the ventricle at all sites
studied. In all cases, when the coupling intervals of premature extrastim-
uli were plotted against the return cycle (As-Ar), an increasing resetting re-
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1724-61 Resetting Responses During Atrioventricular Nodal
Reentrant Tachycardia Suggest an Anisotropic
Mechanism
Kevin M. Monahan. Noel G. Boyle, Marco Zardini, Panos Papageorgiou,
Joseph Zebede, Mark E. Josephson. Beth Israel Hospital, Boston, MA
We hypothesized that an anatomically determined circuit should have an
identical excitable gap regardless of the site of stimulation. while a func-
tional anisotropic circuit could show differences depending on stimulation
site. In order to explore the nature of the reentrant circuit. and to characterize
the excitable gap during atrioventricular nodal reentrant tachycardia (AVNRT),
we determined the resetting response patterns in eight patients with typical
AVNRT (meantachycardia cycle length (TCl) 346 ± 18 msec). Premature atrial
stimuli were delivered during tachycardia from the area of the slow pathway
(SPI in 7 patients, the fast pathway (FP) in 6 patients, and the ventricle (V)
in 7 patients and the subsequent return cycles (As-Ar) were analyzed. In all
patients. two or more sites were stimulated. Ventricular extrastimulation em-
ployed double extrastimuli such that the first extrastimulus did not interact
with the circuit and acted as a conditioning stimulus. The excitable gap was
defined as the range of coupling intervals from first reset to tachycardia ter-
mination.
Duration of Excitable Gap (msec) by Stimulation Site
AT pts were predominantly female. Othervvise, AT and ATYP were not sep-
arated by tc Cl or intervals before Ad, or by dynamic relationships of intervals
analysed by linear correlation. Thus, Ad is not a useful pharmacologic probe
for differentiation of AT from ATYP when tc terminates without prior AVnode
block.
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1724-41 Coexistence of Typical and Atypical Atrio-ventricular
Nodal Reentry: Evidence for MUltiple Pathways of
Slow Conduction
Marco Zardini, Noel G. Boyle, Kevin M. Monahan, Panos Papageorgiou, Mark
E. Josephson, Claudio D. Schuger. Beth Israel Hospital, Boston, MA
The nature of the atrio-ventricular nodal (AVN) reentry circuit is still a source
of debate. We studied two patients in which both typical (slow-fast, SF) AVN
reentrant tachycardia and atypical (fast-slow, FS) AVN reentrant echoes could
be elicited with atrial and ventricular stimulation respectively. Discontinu-
ous antegrade and retrograde AVN curves were present in both patients, as
shown below:
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sponse pattern was obtained. There was no decremental conduction over
the retrograde FPwith V stimulation.
Conclusions: 1) The reentrant circuit of AVNRT can be reset from multiple
sites. 2} The circuit as a whole demonstrates partial excitability with hetero-
genicityof conduction over individual pathways. 3) A difference in the mea-
sured excitable gap of >20 msec dependent on stimulation site was seen in
5/8 patients and suggests a functionally determined circuit and anisotropic
reentry.
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1725-1 I Long-term Impact of a Patent Infarct-related Artery:
1-Year Survival In the GUSTO Trial
Joseph A. Puma, Michael H. Sketch. Jr., R. John Simes, Douglas C. Morris. Eric
J. Topol, Robert M. Califf, GUSTO Investigators. Duke University Medical Center,
Durham, N.C.
The "open-artery" hypothesis has been validated in the acute phase of coro-
nary occlusion. Controversy remains regarding long-term survival and the
need for revascularization. To examine the long-term impact of a patent
infarct-related artery in the GUSTO trial, we evaluated prospectively collected
data on 41,021 patients treated with thrombolytic therapy for acute infarc-
tion. Patency data were available in 12,864 patients undergoing their first
post-infarction angiogram who had no prior history of PTCA or CABG and
who were not enrolled in the angiographic substudy. The infarct-related artery
was open in 8,810 and closed in 4,054 patients. In the open artery cohort,
50% were treated medically, 38% with PTCA, and 12% with CABG. The cor-
responding percentages in the closed artery cohort were 45, 41 and 14, re-
spectively.
Baseline demographics, risk factor profiles, extent of disease and time to
treatment were similar for both groups. Patients with a closed artery had a
slightly higher incidence of Killip Class III and IV than the open artery cohort
(2% vs 1%). As expected, patients treated medically and with PTCA in both
groups had a preponderance of 1 and 2 vessel disease and patients treated
with CABG had a preponderance of 2 and 3 vessel disease.
1-Year Mortality Open Artery Closed Artery P-value
- Medical Therapy (%) 33 8.5 <0001
-PTCA(%I 2.5 88 <0.001
-CABG(%I 4.2 9.6 <0.001
Conclusion: Infarct-related artery patency confers a survival advantage at
1-year across all thrombolytic treatment strategies in patients with acute my-
ocardial infarction.
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Long Term Outcome After Early Prehospltal Initiated
Thrombolysis
Marc A. Brouwer, Jenny S. Martin, Mark J. Wirkus, Charles C. Maynard, Paul
E. Litwin, Freek W.A. Verheugt, W. Douglas Weaver, MITI Pre-Hospital Study
Investigators. University of Washington, Seattle. WA
In order to determine the long-term effects of very early thrombolytic treat-
ment on outcome after myocardial infarction. patients (pts) in the MITI pre-
hospital thrombolysis trial were assessed for cardiac events (death. admis-
sion for angina, myocardial infarction. congestive heart failure, revascular-
ization) during a mean period of 33 months follow-up. Outcome in 175 pre-
hospital treated pts (PH-group) was compared to 185 pts allocated to treat-
ment after hospital arrival (H-group). The median time from symptom onset
to treatment for the PH-group was 77 min. (56, 101; 25. 75th percentile). and
forthe H-groupwas 110 min. (85,140). Survival at two years was 89% forthe
PH-group and 91 % forthe H-group (p = 0.46). Event free survival at two years
was 51% and 60%, respectively Ip ~ 0.69). The event rate (# events/100
treated ptslfollow-up year) was 34.2 in the PH-group and 41 .0 for the H-group
(p = 0.28).
Pts treated within 70 min. after symptom onset (n = 82) had improved sur-
vival at the time of discharge. 98.8% vs. 91.3%, but in a multi-variate analysis.
subsequent mortality after discharge was related to older age. a history of
heart failure, or prior bypass surgery but not initial time to treatment.
Conclusion: In the MITI prehospital trial, the short and long-term outcome
for pts receiving pre-hospital and hospital initiated thrombolyses is similar.
Time to treatment is an important predictor of hospital mortality but does not
affect the likelihood of survival in the years afterdischarge.
04:30
Extent of Early ST Segment Elevation Resolution: Not
Only a Strong Predictor of Outcome in Patients with
Acute Myocardial Infarction but Also a Sensitive
Measure to Prove the Superiority of a Thrombolytic
Agent?
Rolf Schroder, Karl Wegscheider. INJECT TRIAL Group. Free University Berlin.
Germany
Data from small prospective studies and a retrospective analysis of 1516 pa-
tients of the ISAM study showed that applying two cutoff points with ST el-
evation resolution of 1) ~70%, 2) <70-30%, 3) <30->0% 3 hours after start
of thrombolysis is most efficient to predict infarct size, left ventricular func-
tion, and survival with follow up 6 years regardless of whether patients have
had streptokinase or placebo treatment. A beneficial effect of thrombolytic
therapy was related to a larger proportion of patients with ~70% ST resolu-
tion and less <30% ST resolution (p = 0.0000). In multivariate analysis. ST
resolution <30% was the most powerful independent predictor of early mor-
tality (JACC 1994; 24: 384). In an ECG substudy on all German patients of
the INJECT TRIAL (Multicentre study aimed to compare the efficiency of 1.5
MU Streptokinase with 2 x 10 MU r-PA [Reteplase]bolus injection in 6000
patients). the prognostic power of these ECG markers shall be assessed
prospectively in all patients and in the two treatment groups. From an overall
interim analysis (still blinded to treatment group) on 1118 patients, number
of patients II and percentages of deaths at 3 month follow up for the three
groups of ST elevation resolution are shown in the table:
Anterior MI INa = 531)
5T Resolution :>:70% (165) <70-30% (198) <30% (1681
Mortality 4.2% 17) 5.6%(11} 17.3% (29)
Inferior MI (No = 587)
5T Resolution :>:70% (355) <70-30% (120) <30% (112)
Mortality 3.1%(11) 7.5%(9) 14.3%(16)
Final data on about 2000 patients including significance of differences be-
tween the two thrombolytic agents will be presented at the meeting.
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Late Survival Following Early Coronary Intervention
After Fibrinolytic Therapy with Streptokinase in Acute
Myocardial Infarction (Results of a randomized trial:
SIAM-I)
Bernd Hammer. Cern Ozbek, Armin Heisel, Wolfgang Bay, Gunther Berg.
Benno Hennen, Klaus-Dieter Heib, Markus Hohn, Hauke Tager. Hermann Schieffer,
SIAM Study Group. Medizinische Universittitsklinik Homburg/Saar, Germany
324 pts with acute myocardial infarction were treated with intravenous Strep-
tokinase «4 hrs after onset of symptoms. 1.500.000 U/1 hr) in 13 acute care
hospitals and were centrally randomized by phone call to the university hos-
pital in two groups during fibrinolysis.
Group A: (invasive strategy) CA with PTCA/CABS 14 to 48 hours after start
of treatment and predischarge control CA.
Group B: Icontrol group) no CA within the first 21 days, unless there is evi-
dence for ischemia and predischarge control CA.
In Gr-A 14/158 (=9%) pts. in Gr-B 10/166 (=6%) pts died before hospi-
tal discharge (n.s.). In a follow-up period of at least 24 months (Median 35
months) 13/1441=9%) pts of Gr-A and 14/156 (=9%) pts of Gr-B died (n.s.).
All other patients (n = 273; Gr-A: 131, Gr-B: 142) were followed for a me-
dian time of 76 months (30 - 89 months. 1723 patient years). In Gr-A 20/131
(= 15%) pts and in Gr-B 7/142 (=5%) pts died during this period (p < 0.008).
Cumulative number of deaths in Gr-A and Gr-B
Time Gr-A Gr-B p-value
<14 hrs 3(~2%1 3(~2%) n.s.
14--48 hrs 9(=6%) 8(=5%) n.s.
in-hospital 14(~9%) 10(~6%) n.s.
3-year-FU 27 (~17%) 24(~14%) n,s.
6-year-FU 47 (=30%) 31 (~19%) <0.03
Conclusion: This data exclude even a long-term superiority of an invasive
approach to patients with fibrinolytic treated acute myocardial infarction. A
detailed stratification to identify patients who will benefit from coronary inter-
vention is needed.
